Article Detail

Home > Article Detail
  • P-ISSN 1225-0163
  • E-ISSN 2288-8985

Antitumor agents bound to silica nanoparticles : potential technology for the remediation of malignant tumors

Analytical Science and Technology / Analytical Science and Technology, (P)1225-0163; (E)2288-8985
2010, v.23 no.6, pp.579-586
https://doi.org/10.5806/AST.2010.23.6.579



  • Downloaded
  • Viewed

Abstract

Commercially widely used antitumor agents such as hydroxy urea, 6-mercaptopurine monohydrate,cytosine arabinoside, cyclophosphamide monohydrate and uracil were reacted with 3-(triethoxysilyl)propyl isocyanate and the product hydrolyzed to give silica nanoparticles bound antitumor agents ranging from 10 nm to micron-sized aggregates. The silyl isocyanate derivative was also reacted neat with water to give hybrid organicsilica nanoparticles containing -CH2-CH2-CH2-NH-COOH or the corresponding decarboxylated propylamine groups depending on solvent and temperature employed. In vitro tests these functionalized silica nanoparticles were effective in the treatment of malignant tumor cells but had little or no effect on normal cells. Malignant human lung, ovarian, melanoma, CNS(Central nervous system) and colon tumor cells were used in this research. The use of silica as a carrier medium in the present research serves as a model material due to its ready functionalization via silation. The proof of concept established by the results suggests that the technique may be applied to other, more biocompatible carrier nanoparticles.

keywords
silica nanoparticle, antitumor agents, 3-(triethoxysilyl)propyl isocyanate


Reference

1

1. Higashi, Sohei (Nanocarrier Co., Ltd., Japan). Farumashia 2002, 38(4), 345-346 (Japan).

2

2. (a) Xu, Jingya (Fannin Bioscience, Inc., USA) PCT Int. Appl. WO 00 61,788 (C1. C12Q), 19 Oct 2000, US Appl. 291,234,13 Apr 1999; 65pp. (Eng).

3

(b) Rihova, B. (Polymer Materials Research Group, University of Gent, 9000 Ghent, Belg.). Proc. Int. Symp. Controlled Release Bioact. Mater. 1999, 26th, 627- 628 (Eng).

4

(b) Deggi, Neil P; Soon-Shiong, Patrick; Magdassi, Shlomo; Sahadevan, David D. (Vivorx Pharmaceuticals, Int., USA) PCT Int. Appl. WO 99 00,113 (C1. A61K9/ 22), 7 Jan 1999, US Appl, 926,155,9 Sep 1997; 175pp. (Eng).

5

(d) Lavi, Sara; Satchi-Fainaro, Ronit (Ramot-University Authority for Applied Research and Industrial Development Ltd., Israel) PCT Int. Appl. WO 02 07,670 (C1. A61K), 31 Jan 2002, US Appl. 668,714, 22 Sep 2000; 66pp. (Eng).

6

(e) Lavi, Sara; Satchi-Fainaro, Ronit (Ramot-University Authority for Applied Research and Industrial Development Ltd., Israel) PCT Int. Appl. WO 02 07,671 (C1. A61K), 31 Jan 2002, US Appl. 668,713, 22 Sep 2000; 73pp. (Eng).

7

(f) Fotinos, Spiros; O’Halloran, David; Zolotarsky, Yelena (Lavipharm Laboratories Inc., USA) PCT Int. Appl. WO 02 54,997 (C1. A61F13/00), 18 Jul 2002, US Appl. PV260, 587, 9 Jan 2001; 20pp. (Eng).

8

(g) Liggins, Richard; Murphy, Larry; Guan, Dechi (Angioteth Pharmaceuticals Inc., Can.) PCT Int. Appl. WO 02 72,150 (C1. A61K47/48), 19 sep 2002, US Appl. PV337,935, 7 N

9

3. Nizard, Philippe; Gross, David-Alexandre; Chenal, Alexandre; Beaumelle, Bruno; Kosmatopoulos, Konstadinos; Gillet, Daniel (Deparetment d’Ingenierie et d’Etudes des Proteines, CEA-Saclay, 91191 Gif-sur-Yvette, FR.). Journal de la Societe de Biologie 2001, 195(3), 229- 234(Fr).

10

4. Unger, Gretchen M. (Genesegues, Inc., USA) PCT Int. Appl. WO 01 64,164 (C1. A61K), 7 Sep 2001, US Appl. PV185,282, 28 Fed 2000; 70 pp. (Eng).

11

5. (a) Burman, Anand C.; Mukherjee, Rama; Khattar, Dhiraj; Kumar, Mukesh; Bala, Honey; Shrivastava, Rajiv Kumar (Dabur Research Foundation, India) U.S. US 6,365,191 (C1. 424-489; A61K9/14), 2 Apr 2002, IN Appl. 2000/DE641, 11 Jul 2000; 8 pp., Cont.-in-part of U.S. Ser. No. 401,927. (Eng).

12

(b) Maitra, Amarnath; Sahoo, Sanjeeb Kumar, Ghosh, Prasanta Kuma; Burman, Anand C.; Mukherjee, Rama; Khattar, Dhiraj; Kumar, Mukesh; Paul, Soumendu (Dabur Research Foundation; Delhi University, India) U.S. US 6,322,817 (C1. 424-489; A61K47/30), 27 Nov 2001, IN Appl. 1999/DE263, 17 Feb 1999; 10 pp. (Eng).

13

6. Fukumori, Yoshinobu; Ichikawa, Hideki; Tokumitsu, Hiroyuki; Shikata, Futoshi; Miyamoto, Masahito; Watanabe, Testuya (Faculty of Pharmaceutical Sciences and High Technology Research Center, Kobe Gakuin University, Kove, Japan 651-2180), Int. Conf. Process. Mater. Prop. Proc., 2nd 2000, 453-458 (Eng).

14

7. Da Silverira, Monza; Ponchel, Gilles; Duchene, Dominique; Couvreur, Patrick; Puisieux, Francis (Bioalliance Pharma (S.A.); Monza Da Silverira, Airton, Fr.) PCT Int. Appl. WO 99 43,359 (C1. A61K47/48), 2 Sep 1999, FR Appl. 1998/2,429, 27 Feb 1998; 56 pp. (Fr).

15

8. Balland, Olivier; Saison-Behmoaras, Tula; Garestier, Therese; Helene, Claude (Laboratorie de Biophysique, Museum National Histoire Naturelle, 75231 Paris, Fr.). NATO ASI Ser., Ser. A 1996. 290 (Targeting Drugs 5), 131-142 (Eng).

16

9. Jain, S; Jain, N. K. (Department of Pharmaceutical Sciences, DR. H. S. Gour University, Sagar, 470003 India). Proc. Int. Symp. Controlled Release Bioact. mater. 1997, 24th, 857-858 (Eng).

17

10. R. Partch; E Powell; Y-H Lee; M. Varshney; S. Kim; N. Barnard; D. Shah; D.Dennis; T. Morey. 2003 Kluwer Academic publishers, Y, G, Gogotsi and I. V. Uvarova (eds.), 27-40.

  • Downloaded
  • Viewed
  • 0KCI Citations
  • 0WOS Citations

Other articles from this issue

Recommanded Articles

상단으로 이동

Analytical Science and Technology